Vitro Biopharma Launches New Bioanalytical Services and Novel Stem Cell-Derived Renal & Neural Cells

GOLDEN, CO / ACCESSWIRE / September 22, 2015 / Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma, announced expansion of its product/service offerings to include biomarker profiling services and stem cell derived neuronal and renal cells. Vitro Biopharma’s new services include simultaneous determination of several molecules through multi-plexed assays. The cells of our bodies communicate with each other through the secretion of numerous bioactive substances that control fundamental physiological and pathological conditions. Our new services offer precise measurement of numerous different signaling molecules at once including cytokines, growth factors, hormones and other biological signaling molecules. We offer panels of biomarkers for analysis of the several organ systems and pathological states of the body: cancer, cardiovascular, immunology/inflammation, metabolism/endocrine, neurology and toxicology. Within each category we offer several panels of individual biomarker groups.

Measurement of biological signaling systems through biomarker profiling provides a snap-shot of the body’s molecular physiology & pathophysiology. This information is critical to the development of new drugs to treat disease and to the assessment of the effectiveness of treatments.

Furthermore, multiple biosignaling pathways can be analyzed at once. Activation of neural stem cells within the brain results in proliferation, migration and gene expression alterations that can lead to regeneration of damaged tissue in various neurological conditions. Vitro Biopharma is developing a Phase I clinical trial for traumatic brain injury (TBI) involving primary endpoints of safety together with secondary endpoints that measure specific biomolecules related to extent of injury, regeneration of cells (including nerve, glial and vascular endothelial cells), neuroprotection, anti-inflammation and blockage of cell death. Vitro Biopharma owns patent-pending technology now being further developed into diagnostic tools to determine stem cell activation and resulting biological processes leading to brain regeneration. Our clinical trial is supported by a substantial amount of preclinical data showing efficacy in animals & we intend to translate this research into a series of clinical studies.

Vitro Biopharma’s new cell line products feature continued expansion of its offering of progenitor-derived, terminally-differentiated cells for use in toxicology and regenerative medicine. The new cells include dopaminergic neurons and a type of renal cell, proximal tubule epithelial cells, that control the content of waste products in the urine. These products extend our stem cell-derived cells to include cardiac, neural and renal cells. Together with hepatocytes, the new cells enable development of in-vitro toxicology systems to evaluate liver, cardiac, neural and renal toxicity. Also, since progenitors are derived from MSCs, our new products expand potential for the development of bioengineered organs, e.g., critical functional cells of the kidney together with a bioengineered vasculature as an artificial kidney using patient-specific cells.

The developer of these new cell lines, Tiana Tonrey, MS/Toxicology, Vitro Biopharma’s Lab Manager said, “We are pleased to offer our new products and services that enhance our capabilities to support the expanding field of stem cell based toxicology/drug testing as well as therapy for organ failure and other regenerative medicine applications. Our cells and media are designed to support use of these cells in various applications in applied research and drug testing. Our biomarker profiling services provide completely validated, quantitative assays for analysis of serum, plasma or cell culture media featuring non-detectable levels of cross-reactivity between different biomarkers.”

About Vitro Biopharma

Vitro Biopharma’s mission is “Harnessing the Power of Cells(TM)” for the advancement of regenerative medicine to its full potential. Vitro Biopharma operates within a modern, GMP-compliant biotechnology manufacturing and R&D facility in Golden, Colorado. Vitro Biopharma manufactures and sells “Tools for Stem Cell and Drug Development(TM),” including human mesenchymal stem cells and derivatives, the MSC-Gro(TM) Brand of optimized media for MSC self-renewal and lineage-specific differentiation. Our cell lines also include cancer-associated fibroblasts (CAFs) and MSC- derived progenitor cells, including neural stem cells as well as a growing line of terminally differentiated cells: alpha-motor neurons, osteoblasts, chondrocytes, cardiomyocytes, proximal tubular epithelial cells, etc. A key target of these terminally differentiated cells is their use in cell-based assays of pre-clinical toxicology of drugs, drug candidates and drug combinations that may produce toxic effects on cardiac, neural or renal cells either as drugs or drug metabolites derived from interaction with specific cells such as liver cells. Vitro Biopharma is developing clinical products through various partnerships that include providing its clinical grade media for expansion of stem cells prior to transplantation and preliminary studies of stem cell activation in ASD & autoimmunity in central Europe. More detail is provided on its website: (www.vitrobiopharma.com).

Vitro Biopharma received the Frost and Sullivan Technology Innovation Leadership Award for the industry sector: Stem Cell Tools and Technology in North America, 2014.

Safe Harbor Statement

Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements are identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Dr. James Musick
Chief Executive Officer
Vitro Biopharma
(303) 999-2130 Ext. 3
E-mail: jim@vitrobiopharma.com

SOURCE: Vitro Diagnostics, Inc.

ReleaseID: 432137